Key result
mRNA COVID-19 vaccine myocarditis features ongoing symptoms in 35% at 12-18 months despite mild clinical severity.
Why the study?
Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccination remained an important but undefined public health concern.
What are the medium-to-long term clinical outcomes and symptom persistence in individuals with myocarditis following mRNA COVID-19 vaccination?
Cohort (n=256)
Yes
What are the medium-to-long term clinical outcomes and symptom persistence in individuals with myocarditis following mRNA COVID-19 vaccination?
Answers are grounded in this paper and cite their sources.
While a significant proportion of patients with mRNA COVID-19 vaccine-associated myocarditis experience ongoing symptoms at 12-18 months, the clinical course is generally mild with no deaths, supporting continued vaccine use.
Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern. We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia. Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild, with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-risk individuals to prevent disease caused by SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2025) conducted a cohort in Myocarditis following mRNA COVID-19 vaccination (n=256). mRNA COVID-19 vaccination was evaluated on Ongoing symptoms at 12-18 months. Among individuals with myocarditis following mRNA COVID-19 vaccination, 35% reported ongoing symptoms at 12-18 months, though clinical severity remained mild with low hospitalization rates and no deaths.
Synapse has enriched 10 related papers. Consider them for comparative context: